Allergy and Immunology · East Brunswick, NJ
NPI
1114122033
Since 2007
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
557 Cranbury Rd Ste 3
East Brunswick, NJ, 08816
Phone (732) 613-0600
Groups this clinician bills Medicare through
Medicare paid, 2024
$82K
9,178 services
Medicare patients, 2024
234
Average age 72
Drug cost, 2024
$525K
654 prescriptions
Company payments, 2025
$1,202
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sara H Axelrod-Malagold was code 95004 (test - miscellaneous), 6,860 times for 94 patients. In total Sara H Axelrod-Malagold billed 9,178 services in 21 codes, and Medicare paid $82K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-10-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 6,860 | 94 | $3.49 | $24K |
| 95024 Test - Miscellaneous | Office | 1,020 | 60 | $7.59 | $7,745 |
| 95117 Treatment - Miscellaneous | Office | 246 | 20 | $10.51 | $2,584 |
| 99214 Office E&M - Established | Office | 177 | 125 | $110.03 | $19K |
| 95018 Test - Miscellaneous | Office | 140 | 19 | $18.81 | $2,633 |
| 96372 Injection Administration | Office | 126 | 21 | $10.85 | $1,367 |
| 99204 Office E&M - New | Office | 64 | 64 | $139.33 | $8,917 |
| 99203 Office E&M - New | Office | 57 | 57 | $96.37 | $5,493 |
| 99213 Office E&M - Established | Office | 39 | 33 | $82.71 | $3,226 |
| 95076 Test - Miscellaneous | Office | 19 | 16 | $113.11 | $2,149 |
| 95012 Pulmonary | Office | 14 | 11 | $15.96 | $223 |
By year: 2022 $75K for 9,332 services; 2023 $84K for 9,736 services; 2024 $82K for 9,178 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sara H Axelrod-Malagold prescribed most often to Medicare patients was Montelukast Sodium, with 116 prescriptions and refills. In total Sara H Axelrod-Malagold wrote 654 Medicare prescriptions that cost $525K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 116 | 278 | 37 | $1,621 |
| Dupixent Pen Dupilumab | 59 | 70 | Under 11 | $272K |
| Ipratropium Bromide Generic | 52 | 78 | 21 | $1,713 |
| Carbinoxamine Maleate Generic | 30 | 44 | Under 11 | $3,285 |
| Xolair Omalizumab | 29 | 29 | Under 11 | $80K |
| Fluticasone Propionate Generic | 29 | 61 | 14 | $645 |
| Levocetirizine Dihydrochloride Generic | 23 | 41 | Under 11 | $463 |
| Dupixent Syringe Dupilumab | 22 | 26 | Under 11 | $99K |
| Triamcinolone Acetonide Generic | 21 | 23 | 18 | $271 |
| Breo Ellipta Fluticasone/Vilanterol | 21 | 21 | Under 11 | $8,265 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 18 | 28 | Under 11 | $2,774 |
| Azelastine Hcl Generic | 17 | 29 | Under 11 | $290 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 14 | 16 | 11 | $567 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 14 | 14 | Under 11 | $8,971 |
| Epinephrine Generic | 13 | 13 | 11 | $2,408 |
Brand drugs: 242 claims; generic drugs: 412 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sara H Axelrod-Malagold $1,202 ($1,202 in general payments such as food, travel and fees) from 14 companies. The largest payer was Genzyme Corporation with $261.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 15 | $261 |
| Regeneron Healthcare Solutions, Inc. REGN | 8 | $229 |
| Novartis Pharmaceuticals Corporation NVS | 15 | $181 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $100 |
| Optinose US, Inc. | 5 | $84.2 |
| Lilly USA, LLC LLY | 4 | $77.31 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $72 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 3 | $42.48 |
| Amgen Inc. AMGN | 2 | $35.48 |
| Organon LLC OGN | 2 | $34.04 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.